4
Registered trials
2
Recruiting
3
Unique sponsors
3
Unique IMPs
3
Commercial trials
Drug classes (ATC)
—
ATC code not specified
4
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Monoclonal antibody (primate)
1 substance
Phase II:
1
Phase I (Other):
1
Phase I (First in Human):
2
Phase II
1 trial-
RecruitingUnicancer AcademicIVONESCIMAB
Phase I (Other)
1 trial-
EndedAmgen Inc. CommercialIMP not specified
Phase I (First in Human)
2 trials-
EndedAmgen Inc. CommercialAMG 193
-
RecruitingDaiichi Sankyo Inc. CommercialDS-3939A
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Amgen Inc. | Commercial | 2 | Phase I (Other), Phase I (First in Human) | 0 |
| Daiichi Sankyo Inc. | Commercial | 1 | Phase I (First in Human) | 1 |
| Unicancer | Academic | 1 | Phase II | 1 |
New trials by year
2022
1
2024
1
2025
2